Etiopathogenesis of ankylosing spondylitis (AS), a major subtype of a group of chronic inflammatory diseases known as spondyloarthropathies, is not clearly understood yet. In this study, we aimed to investigate the interleukin 23 (IL-23)/interleukin-17 (IL-17) pathway, which is a new cytokine pathway in inflammatory diseases. We evaluated serum IL-17 and IL-23 levels after 1-year follow-up in AS patients using only nonsteroidal anti inflammatory drugs (at need or continue). Forty-four AS patients and 40 healthy controls were included in the study. Clinical evaluations of disease activity were performed. Serum tumor necrosis factor-α (TNF-α), IL-6, IL-17, and IL-23 levels were evaluated. IL-17 and IL-23 levels of the patient group at baseline and 12 months were lower than the control group. There was no significant difference between the baseline and 12th month evaluations of the patient group. TNF-α levels were similar in all groups (in the baseline and 12th month of the patient group and in the control group). Although our results are in contrast to the literature findings, the IL-23/IL-17 pathway is a newly discovered pathway, and there may still be unknowns. New studies involving larger patient groups are needed for the factors affecting serum IL-23/IL-17 levels in patients with AS. We also think that it will be useful to make more comprehensive and long-term studies about which patients will respond well to IL-23/IL-17 blockade.

中文翻译：

---

用非甾体类抗炎药治疗的强直性脊柱炎患者的血清白细胞介素23/17水平：一项前瞻性队列研究。

强直性脊柱炎（AS）的病因尚未明确了解，这是一组慢性炎症性疾病的一种主要亚型，被称为脊椎关节病。在这项研究中，我们旨在研究白介素23（IL-23）/白介素17（IL-17）途径，这是炎性疾病中的一种新的细胞因子途径。我们在仅使用非甾体类抗炎药（需要或继续使用）的1年随访中评估了AS患者的血清IL-17和IL-23水平。该研究包括44名AS患者和40名健康对照。进行了疾病活动的临床评估。评估血清肿瘤坏死因子-α（TNF-α），IL-6，IL-17和IL-23的水平。患者组在基线和12个月时的IL-17和IL-23水平低于对照组。患者组的基线评估与第12个月评估之间没有显着差异。所有组中的TNF-α水平相似（在患者组的基线和第12个月以及对照组中）。尽管我们的结果与文献发现相反，但IL-23 / IL-17途径是一个新发现的途径，可能仍然未知。影响AS患者血清IL-23 / IL-17水平的因素还需要涉及更大患者群体的新研究。我们还认为，对哪些患者对IL-23 / IL-17阻断反应良好，进行更全面和长期的研究将非常有用。尽管我们的结果与文献发现相反，但IL-23 / IL-17途径是一个新发现的途径，可能仍然未知。影响AS患者血清IL-23 / IL-17水平的因素还需要涉及更大患者群体的新研究。我们还认为，对哪些患者对IL-23 / IL-17阻断反应良好，进行更全面和长期的研究将非常有用。尽管我们的结果与文献发现相反，但IL-23 / IL-17途径是一个新发现的途径，可能仍然未知。影响AS患者血清IL-23 / IL-17水平的因素还需要涉及更大患者群体的新研究。我们还认为，对哪些患者对IL-23 / IL-17阻断反应良好，进行更全面和长期的研究将非常有用。